Lexeo Therapeutics, Inc.
LXEO
$5.09
-$0.41-7.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -87.50M | -99.96M | -104.97M | -114.17M | -109.31M |
| Total Depreciation and Amortization | 2.12M | 2.08M | 2.06M | 2.04M | 2.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.84M | 8.84M | 9.62M | 10.70M | 13.83M |
| Change in Net Operating Assets | -20.45M | -9.52M | -13.52M | 6.37M | 5.45M |
| Cash from Operations | -97.99M | -98.56M | -106.81M | -95.07M | -88.00M |
| Capital Expenditure | -432.00K | -397.00K | -397.00K | -191.00K | -296.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.96M | -89.86M | -81.75M | -117.05M | -77.99M |
| Cash from Investing | -78.39M | -90.25M | -82.15M | -117.24M | -78.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -495.00K | -533.00K | -480.00K | -508.00K | -460.00K |
| Issuance of Common Stock | 236.51M | 234.08M | 80.33M | 80.23M | 6.90M |
| Repurchase of Common Stock | -- | -- | -4.00K | -4.00K | -17.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.78M | -16.75M | -6.92M | -6.92M | -6.29M |
| Cash from Financing | 219.24M | 216.80M | 72.93M | 72.80M | 133.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.86M | 27.98M | -116.03M | -139.51M | -166.15M |